Meeting
2016 ASCO Annual Meeting
A phase I study of MLN0128 and bevacizumab in patients with recurrent glioblastoma and other solid tumors.
Authors
Lakshmi Nayak
Dana-Farber Cancer Institute, Boston, MA
Lakshmi Nayak , John L. Hays , Alona Muzikansky , Sarah C. Gaffey , Khanh Tu Do , Vinay K. Puduvalli , Eudocia Quant Lee , Mikael L. Rinne , Andrew David Norden , Rameen Beroukhim , Patrick Y. Wen , L. Austin Doyle , Helen X. Chen , Geoffrey Shapiro , David A. Reardon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT02142803
Citation
J Clin Oncol 34, 2016 (suppl; abstr 2013)
DOI
10.1200/JCO.2016.34.15_suppl.2013
Abstract #
2013
Poster Bd #
202
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 1 study of TPST-1495 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors.
First Author: Susanna Varkey Ulahannan
Poster
2015 ASCO Annual Meeting
A phase I trial everolimus and sorafenib in patients with recurrent high-grade gliomas: Brain Tumor Treatment Collaborative trial 09-01.
First Author: Jeffrey J. Raizer
Poster
2014 ASCO Annual Meeting
Phase I study of plerixafor and bevacizumab in recurrent high-grade glioma.
First Author: Katrina H. Smith
Poster
2013 ASCO Annual Meeting
Phase I study of anti-PlGF monoclonal antibody (mAb) RO5323441 (RO) and anti-VEGF mab bevacizumab (BV) in patients with recurrent glioblastoma (GBM).
First Author: Ulrik Niels Lassen